Coronavirus Disease 2019 (COVID-19) – Analysis of the Emerging Disease Landscape – March 2020
- Pages: 56
- Published: March 2020
- Report Code: GDHCHT052
-
The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players – from pharma and biotech firms to academic institutions and government agencies – have thrown their hats in the ring.
Scope
Global epidemiology metrics and trends
Snapshot of epidemiological trends to date in the top three most-affected countries
An overview of the pipeline for antivirals and vaccines
Summary of available efficacy data
An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
Highlights in deal-making trends, particularly public-private partnerships
Spotlight on social media coverage
Reasons to buy
Understand the global epidemiology of COVID-19
Obtain a snapshot of epidemiological trends to date in the top three most-affected countries
Access an overview of the pipeline for therapeutics and vaccines
Stay up to date on available efficacy data for pipeline-stage products
View the clinical trials landscape by across key attributes
Get up to speed on highlights in deal-making trends, particularly public-private partnerships
Monitor top trends in social media coverage
Table of Contents
Pricing
Discounts available for multiple report purchases.